Weight-loss drug developer BioAge valued at $758 mln in Nasdaq debut

Reuters09-27

Sept 26 (Reuters) - Shares of BioAge Labs opened 25% above their initial public offering price in their Nasdaq debut on Thursday, valuing the weight-loss drug developer at $757.5 million.

(Reporting by Arasu Kannagi Basil, Prakhar Srivastava, Puyaan Singh and Niket Nishant in Bengaluru; Editing by Sriraj Kalluvila)

((ArasuKannagi.Basil@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment